Ultromics' EchoGo® Amyloidosis Receives FDA Clearance for Cardiac Amyloidosis Detection
Key Insights
Ultromics (search)' EchoGo® Amyloidosis (search), an AI-based software, has received FDA clearance to improve early detection of Cardiac Amyloidosis (search), a frequently underdiagnosed cause of heart failure (search).
EchoGo® Amyloidosis (search) demonstrated high sensitivity (84.5%) and specificity (89.7%) in detecting Cardiac Amyloidosis (search) in individuals aged 65 and older with heart failure (search).
The device, which uses standard echocardiogram images, integrates into clinical workflows, enabling clinicians to identify potential cases efficiently with only a single apical 4-chamber echo video clip.
Ultromics (search) has secured FDA clearance for its EchoGo® Amyloidosis (search), an AI-driven diagnostic tool designed to enhance the early detection of Cardiac Amyloidosis (search). This condition, often underdiagnosed as a cause of heart failure (search), can now be identified more efficiently using standard echocardiogram images. The clearance marks a significant milestone as EchoGo® Amyloidosis is the first device from the FDA’s Total Product Lifecycle Advisory Program (TAP) to achieve marketing authorization.
Advancing Cardiac Amyloidosis Detection
Cardiac Amyloidosis (search) is characterized by the accumulation of abnormal amyloid fibrils in the heart's extracellular matrix, leading to restrictive cardiomyopathy. Early detection is crucial, as patients diagnosed at end-stage disease have significantly shorter survival times compared to those diagnosed early. However, the non-specific presentation of Cardiac Amyloidosis often leads to missed or delayed diagnoses, particularly in patients with heart failure (search) with preserved ejection fraction (HFpEF).
EchoGo® Amyloidosis (search) addresses these challenges by leveraging artificial intelligence to analyze routinely acquired echocardiogram images. Requiring only a single apical 4-chamber view, the device identifies potential cases with high accuracy, even in clinical settings with limited expertise or resources.
Clinical Performance and Validation
Clinical data from the FDA submission demonstrated that EchoGo® Amyloidosis (search) achieved 84.5% sensitivity and 89.7% specificity in detecting Cardiac Amyloidosis (search) within a target population of individuals aged 65 and older with heart failure (search). Consistent performance was observed across various Amyloidosis subtypes, including AL Amyloidosis (84.4% sensitivity), Wild-type Transthyretin Amyloidosis (TTRwt) (85.8% sensitivity), and Hereditary Transthyretin Amyloidosis (TTRv) (86.3% sensitivity).
In a matched subgroup analysis, EchoGo® Amyloidosis (search) maintained excellent diagnostic performance, achieving 83.4% sensitivity and 90.6% specificity when compared to phenotypically similar controls. The device also demonstrated 100% repeatability, ensuring consistent diagnostic outcomes.
Integration and Scalability
EchoGo® Amyloidosis (search) is designed for seamless integration into existing clinical workflows. As a software-only solution, it requires no additional hardware and operates on a Software-as-a-Service (SaaS) model, making it highly scalable and rapidly deployable. The device complements Ultromics (search)’ existing EchoGo® Heart Failure (search) device, providing a comprehensive solution for diagnosing heart failure and its underlying causes.
"Improving the detection of Cardiac Amyloidosis (search) is vital as early detection provides the greatest therapeutic benefit for patients," said Prof. Sanjiv J. Shah, MD, Northwestern University. "Novel AI-based diagnostic tools such as EchoGo® Amyloidosis (search) from Ultromics (search) should help facilitate disease identification, particularly in clinics and hospitals restricted by expertise and resource."
Collaborative Development
The development of EchoGo® Amyloidosis (search) was supported by Janssen Biotech, Inc., a Johnson & Johnson Company, and Pfizer, reflecting their commitment to improving the diagnosis and clinical outcomes of Cardiac Amyloidosis (search). Janssen supported the development of the device, while Pfizer supported expediting the performance testing and validation ahead of the regulatory submission.
With its FDA clearance, EchoGo® Amyloidosis (search) is poised to transform the landscape of Cardiac Amyloidosis (search) diagnosis, enabling earlier detection, improved patient outcomes, and more efficient use of healthcare resources.